Smartlab Europe

News

AstraZeneca and Merck enter licence agreement for investigational oral WEE1 kinase inhibitor therapy for cancer

AstraZeneca announced that MedImmune, its global biologics research and development arm, has entered into a definitive agreement to acquire Amplimmune, a privately-held, Maryland, US-based biologics company focused on developing novel therapeutics in cancer immunology. WEE1...

Statins being overprescribed for growing number of kidney disease patients

A new analysis concludes that large numbers of patients in advanced stages of kidney disease are inappropriately being prescribed statins to lower their cholesterol - drugs that offer them no benefit and may increase other health risks such as...

SAVOR-TIMI 53 sets new standard for cardiovascular outcome trials in diabetes

Uncertainty persists regarding whether drugs that lower sugar reduce the risk of heart attack, with some concerns that diabetes drugs may actually raise the risks. The Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with...

Novartis holds annual healthcare entrepreneur competition

Novartis has invited 60 selected students from leading international universities in 21 countries to its headquarters in Switzerland for the International Biotechnology Leadership Camp (BioCamp). Over the course of three days, students will gain first-hand experience of starting a...

EMA and US FDA release first conclusions of parallel assessment of quality-by-design applications

The European Medicines Agency (EMA) and the United States Food and Drug Administration (US FDA) have published a joint question-and-answer document that outlines the conclusions of their first parallel assessment of quality-by-design (QbD) elements of marketing-authorisation applications. ...

FDA approves new drug to treat HIV infection

The U.S. Food and Drug Administration has approved Tivicay (dolutegravir), a new drug to treat HIV-1 infection. Tivicay is an integrase strand transfer inhibitor that interferes with one of the enzymes necessary for HIV to multiply. It is a...

Novartis first company accredited with global CEO Cancer Gold Standard

Novartis is the first company to earn global CEO Cancer Gold Standard accreditation by the non-profit organization CEO Roundtable on Cancer, a group of cancer fighting CEOs from a variety of industries, including healthcare. The designation recognizes the company's...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »